ArticleNPJ vaccines2026
A single-cycle recombinant VSV vaccine displaying the Hendra virus glycoprotein uniformly protects against Hendra and Nipah virus challenge.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nipah virus in the era of global connectivity: molecular evolution, transmission risk, and preparedness strategies.Virus genes · 2026Review
- A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates.PLoS pathogens · 2026Article
- Comprehensive mapping of human CD4Cell reports. Medicine · 2026Article
- Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance.Emerging infectious diseases · 2026Article
- Oral 4'fluorouridine provides postexposure protection against lethal Nipah virus infection.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hendra (HeV) and Nipah (NiV) are closely related, highly pathogenic paramyxoviruses which cause severe, often fatal disease in humans and animals. There are no approved vaccines to protect humans from HeV or NiV infection, although an ideal vaccine countermeasure should provide a protective immune response against both viruses due to the geographic overlap of the natural bat reservoir and recurrent zoonotic spillover events. Here, we developed a single-cycle, recombinant vesicular stomatitis virus vaccine displaying the HeV (G) glycoprotein (G*rVSV∆G-HeV-G) and performed vaccination, challenge, and passive transfer studies in Syrian golden hamsters. Intramuscular vaccination with a single 1.0E7 PFU dose of G*rVSV∆G-HeV-G uniformly protected from lethal HeV and NiV infection, with neutralizing antibodies elicited by the G*rVSV∆G-HeV-G vaccine identified as a correlate of protection in subsequent passive transfer experiments. Our data indicate that the experimental G*rVSV∆G-HeV-G vaccine is effective in protecting against lethal henipavirus disease in a sensitive animal model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.